tirzepatide and heart rate The Hidden Cost of GLP-1s: What 1,552 Nights of Sleep Data Revealed Weight Loss Drugs: Benefits and

Hasan M, Khatun A, Fukuta T, Kogure K

Risk of Hypoglycemia: While GLP-1 medications are not typically associated with an increased risk of hypoglycemia when used as monotherapy, they may potentiate the effects of other antidiabetic medications that can cause hypoglycemia, such as sulfonylureas or insulin

Key Products: Pemvidutide, balanced 1:1 dual GLP-1/glucagon receptor agonist, designed to drive both appetite suppression (GLP-1) and direct hepatic fat oxidation (glucagon)

Medicines that could lower diabetes risks and simultaneously reduce risks for heart disease and other obesity-related complications could have sizeable benefits in many LMICs where such disease are starting to escalate fast in part due to rising waist girths, said Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow

These factors underscore the importance of considering both clinical trial data and real-world evidence when evaluating the effectiveness of weight management therapies